Antipsychotic medication in schizophrenia: A review

British Medical Bulletin

Volumn 114, Issue 1, 2015, Pages 169-179

  Lally, John ^a   MacCabe, James H ^b  

^a KING'S COLLEGE LONDON   (United Kingdom)

^b SOUTH LONDON AND MAUDSLEY NHS FOUNDATION TRUST   (United Kingdom)

Author keywords

Antipsychotic medication; Psychotic disorders; Schizophrenia

Indexed keywords

ASENAPINE; CLOZAPINE; LURASIDONE; NEUROLEPTIC AGENT; PALIPERIDONE;

ANXIETY DISORDER; ARTICLE; BIPOLAR DISORDER; CARDIOMETABOLIC DISEASE; CARDIOVASCULAR DISEASE; DRUG CHOICE; DRUG EFFICACY; DRUG MECHANISM; DRUG MEGADOSE; DRUG SUBSTITUTION; DRUG TOLERABILITY; DRUG USE; HUMAN; INJECTION; MAINTENANCE THERAPY; MAJOR DEPRESSION; MEDICATION COMPLIANCE; METABOLIC SYNDROME X; PATIENT MONITORING; POLYPHARMACY; PRIORITY JOURNAL; SCHIZOPHRENIA; TREATMENT RESPONSE; UNSPECIFIED SIDE EFFECT; CHEMICALLY INDUCED; DRUG ADMINISTRATION; DRUG RESISTANCE;

ANTIPSYCHOTIC AGENTS; CARDIOVASCULAR DISEASES; CLOZAPINE; DRUG ADMINISTRATION SCHEDULE; DRUG RESISTANCE; DRUG SUBSTITUTION; HUMANS; MEDICATION ADHERENCE; SCHIZOPHRENIA;

EID: 84942052456     PISSN: 00071420     EISSN: 14718391     Source Type: Journal    
DOI: 10.1093/bmb/ldv017     Document Type: Article

References (40)

1. Ginovart N, Kapur S. Role of dopamine D(2) receptors for antipsychotic activity. Handb Exp Pharmacol 2012; 212:27-52.
2. Kapur S, Remington G. Dopamine D(2) receptors and their role in atypical antipsychotic action: still necessary and may even be sufficient. Biol Psychiatry 2001;50:873-83.
3. Howes OD, Murray RM. Schizophrenia: an integrated sociodevelopmental-cognitive model. Lancet 2014;383: 1677-87.
4. Kapur S, Zipursky R, Jones C, et al. Relationship between dopamine D(2) occupancy, clinical response, and side effects: a double-blind PET study of first-episode schizophrenia. Am J Psychiatry 2000;157:514-20.
5. Meltzer HY. Treatment of the neuroleptic-nonresponsive schizophrenic patient. Schizophr Bull 1992;18:515-42.
6. Lieberman JA, Stroup TS, McEvoy JP, et al. Effectiveness of antipsychotic drugs in patients with chronic schizophrenia. N Engl J Med 2005;353:1209-23.
7. Jones PB, Barnes TR, Davies L, et al. Randomized controlled trial of the effect on Quality of Life of second-vs first-generation antipsychotic drugs in schizophrenia: Cost Utility of the Latest Antipsychotic Drugs in Schizophrenia Study (CUtLASS 1). Arch Gen Psychiatry 2006; 63:1079-87.
8. Leucht S, Tardy M, Komossa K, et al. Antipsychotic drugs versus placebo for relapse prevention in schizophrenia: a systematic review and meta-analysis. Lancet 2012;379:2063-71.
9. Leucht S, Hierl S, KisslingW, et al. Putting the efficacy of psychiatric and general medicine medication into perspective: review of meta-analyses. Br J Psychiatry 2012; 200:97-106.
10. Leucht S, Cipriani A, Spineli L, et al. Comparative efficacy and tolerability of 15 antipsychotic drugs in schizophrenia: a multiple-treatments meta-analysis. Lancet 2013;382:951-62.
11. Newcomer JW. Second-generation (atypical) antipsychotics and metabolic effects: a comprehensive literature review. CNS Drugs 2005;1:1-93.
12. Mitchell AJ, Vancampfort D, Sweers K, et al. Prevalence of metabolic syndrome and metabolic abnormalities in schizophrenia and related disorders-a systematic review and meta-analysis. Schizophr Bull 2013;39:306-18.
13. Allison DB, Mentore JL, Heo M, et al. Antipsychoticinduced weight gain: a comprehensive research synthesis. Am J Psychiatry 1999;156:1686-96.
14. Bak M, Fransen A, Janssen J, et al. Almost all antipsychotics result in weight gain: a meta-analysis. PLoS One 2014;9:e94112.
15. Crawford MJ, Jayakumar S, Lemmey SJ, et al. Assessment and treatment of physical health problems among people with schizophrenia: national cross-sectional study. Br J Psychiatry 2014;205:473-7.
16. NICE. Psychosis and schizophrenia in adults: treatment and management (Clinical guideline 178). London: Royal College of Psychiatrists, 2014.
17. Agid O, Kapur S, Arenovich T, et al. Delayed-onset hypothesis of antipsychotic action: a hypothesis tested and rejected. Arch Gen Psychiatry 2003;60:1228-35.
18. Taylor D, Paton C, Kapur S. The Maudsley Prescribing Guidelines in Psychiatry.Wiley, 2012.
19. Robinson D, Woerner MG, Alvir JM, et al. Predictors of relapse following response from a first episode of schizophrenia or schizoaffective disorder. Arch Gen Psychiatry 1999;56:241-7.
20. Girgis RR, Phillips MR, Li X, et al. Clozapine v. chlorpromazine in treatment-naive, first-episode schizophrenia: 9-year outcomes of a randomised clinical trial. Br J Psychiatry 2011;199:281-8.
21. Howes OD, Vergunst F, Gee S, et al. Adherence to treatment guidelines in clinical practice: study of antipsychotic treatment prior to clozapine initiation. Br J Psychiatry 2012;201:481-5.
22. Tiihonen J, Lonnqvist J, Wahlbeck K, et al. 11-year follow-up of mortality in patients with schizophrenia: a population-based cohort study (FIN11 study). Lancet 2009;374:620-7.
23. Cramer JA, Rosenheck R. Compliance with medication regimens for mental and physical disorders. Psychiatr Serv 1998;49:196-201.
24. Leucht S, Heres S. Epidemiology, clinical consequences, and psychosocial treatment of nonadherence in schizophrenia. J Clin Psychiatry 2006;5:3-8.
25. Masand PS, Roca M, Turner MS, et al. Partial adherence to antipsychotic medication impacts the course of illness in patients with schizophrenia: a review. Prim Care Companion J Clin Psychiatry 2009;11:147-54.
26. Valenstein M, Kavanagh J, Lee T, et al. Using a pharmacy-based intervention to improve antipsychotic adherence among patients with serious mental illness. Schizophr Bull 2011;37:727-36.
27. Tiihonen J, Haukka J, Taylor M, et al. A nationwide cohort study of oral and depot antipsychotics after first hospitalization for schizophrenia. Am J Psychiatry 2011;168:603-9.
28. Rosenheck RA, Krystal JH, Lew R, et al. Long-acting risperidone and oral antipsychotics in unstable schizophrenia. N Engl J Med 2011;364:842-51.
29. Correll CU, Rummel-Kluge C, Corves C, et al. Antipsychotic combinations vs monotherapy in schizophrenia: a meta-analysis of randomized controlled trials. Schizophr Bull 2009;35:443-57.
30. Royal College of Psychiatrists. Consensus statement on high-dose antipsychotic medication (CR190). London: Royal College of Psychiatrists, 2014.
31. Yatham LN, Kennedy SH, Parikh SV, et al. Canadian Network for Mood and Anxiety Treatments (CANMAT) and International Society for Bipolar Disorders (ISBD) collaborative update of CANMAT guidelines for the management of patients with bipolar disorder: update 2013. Bipolar Disord 2013;15:1-44.
32. NICE. National Institute for Health and Clinical Excellence. Bipolar disorder (update): the management of bipolar disorder in adults, children and adolescents in primary and secondary care. (Clinical Guideline 185). London: NICE, 2014.
33. Cipriani A, Barbui C, Salanti G, et al. Comparative efficacy and acceptability of antimanic drugs in acute mania: a multiple-treatments meta-analysis. Lancet 2011;378:1306-15.
34. Bauer M, Pfennig A, Severus E, et al. World Federation of Societies of Biological Psychiatry (WFSBP) guidelines for biological treatment of unipolar depressive disorders, part 1: update 2013 on the acute and continuation treatment of unipolar depressive disorders. World J Biol Psychiatry 2013;14:334-85.
35. Joint Formulary Committee. British National Formulary (BNF) 67 Pharmaceutical Press, 2014.
36. Rothschild AJ. Challenges in the Treatment of Major Depressive Disorder With Psychotic Features. Schizophr Bull 2013;39:787-96.
37. Baldwin DS, Anderson IM, Nutt DJ, et al. Evidencebased pharmacological treatment of anxiety disorders, post-traumatic stress disorder and obsessive-compulsive disorder: a revision of the 2005 guidelines from the British Association for Psychopharmacology. J Psychopharmacol 2014;28:403-39.
38. Lally J, Byrne F, Walsh E. A case of paliperidonepalmitate-induced tardive dyskinesia.GenHosp Psychiatry 2013;35:14.
39. Citrome L. Asenapine review, part II: clinical efficacy, safety and tolerability. Expert Opin Drug Saf 2014; 13:803-30.
40. Citrome L. A review of the pharmacology, efficacy and tolerability of recently approved and upcoming oral antipsychotics: an evidence-based medicine approach. CNS Drugs 2013;27:879-911.